Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Updates in the Use of Vamorolone and Steroids in the Treatment of Duchenne Muscular Dystrophy
Bridget McGowan
*
,
Nancy L. Kuntz
*
Corresponding author for this work
Pediatrics
Research output
:
Contribution to journal
›
Editorial
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Updates in the Use of Vamorolone and Steroids in the Treatment of Duchenne Muscular Dystrophy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Duchenne muscular Dystrophy
100%
Vamorolone
100%
Dystrophin Gene
66%
Side Effect Profile
66%
Corticosteroids
66%
First-in-class
33%
Clinical Data
33%
Glucocorticoid Receptor
33%
Treatment Standards
33%
Neuromuscular Disease
33%
Muscle Membrane
33%
Inflammatory Fibrosis
33%
Membrane Stability
33%
Muscle Fibrosis
33%
Partial Agonist
33%
Mineralocorticoid Receptor
33%
Life-limiting
33%
Prevelance
33%
Pharmacology, Toxicology and Pharmaceutical Science
Side Effect
100%
Duchenne Muscular Dystrophy
100%
Vamorolone
100%
Dystrophin
66%
Anti-Inflammatory Drug
33%
Neuromuscular Disease
33%
Myofibrosis
33%
Partial Agonist
33%
Inflammation
33%
Glucocorticoid Receptor
33%
Mineralocorticoid Receptor
33%